Journal of Pediatric Pharmacology and Therapeutics最新文献

筛选
英文 中文
Nontraditional Antiseizure Medications to Consider When Traditional Options Have Failed: Medications for Refractory Seizures and Epilepsies. 传统抗癫痫药物治疗失败时应考虑的非传统抗癫痫药物:治疗难治性癫痫和癫痫的药物。
Journal of Pediatric Pharmacology and Therapeutics Pub Date : 2025-06-01 Epub Date: 2025-06-09 DOI: 10.5863/JPPT-25-01203
Adrian Turner, M Scott Perry
{"title":"Nontraditional Antiseizure Medications to Consider When Traditional Options Have Failed: Medications for Refractory Seizures and Epilepsies.","authors":"Adrian Turner, M Scott Perry","doi":"10.5863/JPPT-25-01203","DOIUrl":"10.5863/JPPT-25-01203","url":null,"abstract":"<p><p>In the field of epilepsy, the advent of precision medicine and the repurposing of medications for new applications have fortuitously allowed more accurate diagnosing and individually targeted therapeutics. Despite these advances, there remain patients who do not respond sufficiently-or at all-to traditionally prescribed treatments. Clinicians often need to be creative, using clinical experience and rigorous research to intuit the next step when most, if not all, anti-seizure treatments have not produced sufficient results. Herein we describe 5 medications with emerging reports of efficacy for seizure control identified by coauthor clinical experience and prescribers in clinical practice for drug information purposes (e.g., ketamine, memantine, quinidine, riluzole, trazodone). Additionally, we summarize pertinent pharmacokinetics, adverse effects, and known and potential interactions with neurologically focused medications to further guide clinical application. Ketamine and memantine appear to be promising options to apply to patients presently, while quinidine, riluzole, and trazodone have data that could contribute to future applications in specific patient populations.</p>","PeriodicalId":37484,"journal":{"name":"Journal of Pediatric Pharmacology and Therapeutics","volume":"30 3","pages":"306-322"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12172677/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144327147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pediatric Antibiotic Stewardship Programs: The Path Forward. 儿科抗生素管理项目:前进之路。
Journal of Pediatric Pharmacology and Therapeutics Pub Date : 2025-06-01 Epub Date: 2025-06-09 DOI: 10.5863/JPPT-25-01200
Jennifer E Girotto, Kristen Nichols, Sara L Ogrin, Sarah Parsons, William S Wilson
{"title":"Pediatric Antibiotic Stewardship Programs: The Path Forward.","authors":"Jennifer E Girotto, Kristen Nichols, Sara L Ogrin, Sarah Parsons, William S Wilson","doi":"10.5863/JPPT-25-01200","DOIUrl":"10.5863/JPPT-25-01200","url":null,"abstract":"<p><p>Antibiotic overuse has been well-documented in all populations, including pediatrics. Pediatric pharmacists are valuable and well-integrated within inpatient antibiotic stewardship programs (ASP) in children's hospitals. The Pediatric Pharmacy Association (PPA) believes all pharmacists, regardless of practice setting, should receive education to support entry-level stewardship activities in pediatric patients. Additionally, pediatric antibiotic stewardship pharmacist leaders should ideally be trained in both infectious diseases (ID) and pediatrics. Currently, specialized training in pediatric ID lacks standardization due to the paucity of subspecialized training opportunities. This paper provides recommendations to support pediatric ASP training, education, and pharmacist staffing for inpatient programs. Further, it is recommended to ensure protected time is available for daily and longitudinal pediatric ASP activities to support optimal care and prevent burnout. Finally, the PPA supports the evolving role of the pediatric pharmacist in the ambulatory ASP arena and recommends investigations into unique payment modalities.</p>","PeriodicalId":37484,"journal":{"name":"Journal of Pediatric Pharmacology and Therapeutics","volume":"30 3","pages":"387-397"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12172678/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144327148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Eslicarbazepine Overdosing in a Teenager: Case Description and Management. 青少年过量使用埃斯卡巴西平:病例描述和处理。
Journal of Pediatric Pharmacology and Therapeutics Pub Date : 2025-06-01 Epub Date: 2025-06-09 DOI: 10.5863/JPPT-24-00076
Maria Kavga, Jobst Rudolf, Foteini Mitsa, Nikolaos Raikos, Maria Fotoulaki, Paraskevi Panagopoulou
{"title":"Eslicarbazepine Overdosing in a Teenager: Case Description and Management.","authors":"Maria Kavga, Jobst Rudolf, Foteini Mitsa, Nikolaos Raikos, Maria Fotoulaki, Paraskevi Panagopoulou","doi":"10.5863/JPPT-24-00076","DOIUrl":"10.5863/JPPT-24-00076","url":null,"abstract":"<p><p>Eslicarbazepine acetate has been recently licensed as an anti-epileptic medication to be used in adolescents. Data regarding dosing and overdosing are still limited in the literature. We describe a rare case of intentional eslicarbazepine overdosing in a previously healthy teenager who presented with neurological toxicity. Management of hyperhydration with diuretics, haloperidol, and midazolam proved to be helpful both in inducing rapid clearance through the kidneys and in managing symptoms of agitation, respectively.</p>","PeriodicalId":37484,"journal":{"name":"Journal of Pediatric Pharmacology and Therapeutics","volume":"30 3","pages":"381-383"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12172686/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144327142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Implementation of Methicillin-Resistant Staphylococcus aureus (MRSA) Nasal Polymerase Chain Reaction (PCR) Screening in Pediatric Patients for De-escalation of Antibiotics. 耐甲氧西林金黄色葡萄球菌(MRSA)鼻聚合酶链反应(PCR)筛查在儿科患者抗生素降级中的应用
Journal of Pediatric Pharmacology and Therapeutics Pub Date : 2025-06-01 Epub Date: 2025-06-09 DOI: 10.5863/JPPT-24-00062
Hannah Bischoff, Katherine Marie Richardson, Beth Addington, Sarah Withers, Carmen Faulkner-Fennell, Heather Hughes
{"title":"Implementation of Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) Nasal Polymerase Chain Reaction (PCR) Screening in Pediatric Patients for De-escalation of Antibiotics.","authors":"Hannah Bischoff, Katherine Marie Richardson, Beth Addington, Sarah Withers, Carmen Faulkner-Fennell, Heather Hughes","doi":"10.5863/JPPT-24-00062","DOIUrl":"10.5863/JPPT-24-00062","url":null,"abstract":"<p><strong>Objective: </strong>Recent literature supports the use of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) nasal polymerase chain reaction (PCR) screening to guide de-escalation of anti-MRSA antibiotics. The objective of this study was to expand on the limited pediatric data, encouraging the use of MRSA nasal PCRs as a tool to guide de-escalation of anti-MRSA antibiotics.</p><p><strong>Methods: </strong>This single center, pre- and post-interventional, retrospective cohort study compared antibiotic regimens in pediatric patients treated empirically with anti-MRSA antibiotics, with and without MRSA nasal PCRs. Use of MRSA nasal PCRs in the pediatric hospital was encouraged following an antimicrobial stewardship provider-led continuing education presentation. The primary outcome was duration of therapy of anti-MRSA antibiotics in days. Secondary outcomes included positive predictive values (PPVs) and negative predictive values (NPVs) for all infections, pneumonia, and skin and soft tissue infections.</p><p><strong>Results: </strong>A total of 319 patients were included in the study, 252 in the pre-intervention group and 67 in the post-intervention group. The duration of anti-MRSA antibiotic therapy in the pre-intervention group was 6.6 days compared with the post-intervention group at 2.0 days (p value = 0.027). Using data from 38 patients with concordant culture results for the infectious diagnosis, overall NPV was calculated as 92.1%. Skin and soft tissue infections and pneumonia were found to have NPVs of 90.1% (22 patients) and 100% (5 patients), respectively.</p><p><strong>Conclusion: </strong>Implementation of MRSA nasal PCRs in pediatric patients significantly reduced the duration of anti-MRSA antibiotic therapy, promoting their utility for antimicrobial stewardship.</p>","PeriodicalId":37484,"journal":{"name":"Journal of Pediatric Pharmacology and Therapeutics","volume":"30 3","pages":"347-351"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12172664/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144327145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inhaled Tobramycin Usage in Critically Ill Pediatric Patients Without Cystic Fibrosis: A Pediatric Pharmacy-Association, Practice-Based Research Network Survey Study. 吸入妥布霉素在无囊性纤维化的危重儿科患者中的应用:一项儿科药学协会基于实践的研究网络调查研究。
Journal of Pediatric Pharmacology and Therapeutics Pub Date : 2025-06-01 Epub Date: 2025-06-09 DOI: 10.5863/JPPT-24-00061
Peter N Johnson, Dominique L Ropp, Courtney Ranallo, Hala Chaaban, Lucila Garcia-Contreras, Stephen Neely, Jamie L Miller
{"title":"Inhaled Tobramycin Usage in Critically Ill Pediatric Patients Without Cystic Fibrosis: A Pediatric Pharmacy-Association, Practice-Based Research Network Survey Study.","authors":"Peter N Johnson, Dominique L Ropp, Courtney Ranallo, Hala Chaaban, Lucila Garcia-Contreras, Stephen Neely, Jamie L Miller","doi":"10.5863/JPPT-24-00061","DOIUrl":"10.5863/JPPT-24-00061","url":null,"abstract":"<p><strong>Objective: </strong>The purpose of this study was to characterize reported usage, dosage regimens, and monitoring practices of inhaled tobramycin in health systems with neonatal intensive care units (NICUs), pediatric intensive care units (PICUs), and cardiovascular intensive care units (CICUs) from the members of the Pediatric Pharmacy Association (PPA). The primary objective was to identify the number of respondents who use an inhaled tobramycin protocol. The secondary objectives included the main indications, dosage regimens, monitoring parameters used, and administration details for inhaled tobramycin.</p><p><strong>Methods: </strong>A cross-sectional questionnaire was distributed to PPA members from March 28-May 22, 2023. Descriptive statistics were employed.</p><p><strong>Results: </strong>The questionnaire was completed by respondents at 79 institutions; respondents at 61 institutions used inhaled tobramycin in PICUs (n = 45; 73.8%), NICUs (n = 36; 59.0%), and CICUs (n = 14; 23.0%). Most respondents (n = 73; 92.4%) in the 61 institutions that use inhaled tobramycin did not have an established protocol. The most common tobramycin product used was a tobramycin nebulization solution, and the most common indication was ventilator-associated tracheitis. Respondents noted the most common dosage regimen was 40 to 80 mg every 8 to 12 hours or 150 mg every 12 hours, regardless of patient age. Most respondents were unaware of the nebulizer used and the location of the nebulizer within the ventilator circuit. Additionally, the respondents noted that their intensive care units do not routinely check tobramycin serum concentrations.</p><p><strong>Conclusion: </strong>Most respondents did not have a standardized inhaled tobramycin protocol. There are variations in the dosage regimen, administration, and monitoring practices in critically ill children receiving inhaled tobramycin. Pediatric clinical pharmacists should work with interprofessional teams, including respiratory therapists and providers, to standardize the use of inhaled antibiotics.</p>","PeriodicalId":37484,"journal":{"name":"Journal of Pediatric Pharmacology and Therapeutics","volume":"30 3","pages":"332-339"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12172681/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144327146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Call for Equal and Equitable Reproductive Health Care Access, Including the Provision of Accurate Education to Pediatric Patients. 呼吁获得平等和公平的生殖保健服务,包括向儿科患者提供准确的教育。
Journal of Pediatric Pharmacology and Therapeutics Pub Date : 2025-04-01 Epub Date: 2025-04-14 DOI: 10.5863/1551-6776-30.2.271
Sarah E Kubes, Caitlyn V Bradford, Samantha Engdahl, P Chase Carpenter, Sara W Hovey
{"title":"A Call for Equal and Equitable Reproductive Health Care Access, Including the Provision of Accurate Education to Pediatric Patients.","authors":"Sarah E Kubes, Caitlyn V Bradford, Samantha Engdahl, P Chase Carpenter, Sara W Hovey","doi":"10.5863/1551-6776-30.2.271","DOIUrl":"10.5863/1551-6776-30.2.271","url":null,"abstract":"","PeriodicalId":37484,"journal":{"name":"Journal of Pediatric Pharmacology and Therapeutics","volume":"30 2","pages":"271-281"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12288579/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144733681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacy Optimization of Antibiotic Verification and Preparation for Pediatric Emergency Department Patients: A Quality Improvement Project. 儿科急诊科患者抗生素验证和制备的药房优化:一项质量改进项目。
Journal of Pediatric Pharmacology and Therapeutics Pub Date : 2025-04-01 Epub Date: 2025-04-14 DOI: 10.5863/1551-6776-30.2.191
Esther Esadah, Elizabeth Ferguson, Kevin Ordons, Jennifer Woodring, Johanna Rosen
{"title":"Pharmacy Optimization of Antibiotic Verification and Preparation for Pediatric Emergency Department Patients: A Quality Improvement Project.","authors":"Esther Esadah, Elizabeth Ferguson, Kevin Ordons, Jennifer Woodring, Johanna Rosen","doi":"10.5863/1551-6776-30.2.191","DOIUrl":"10.5863/1551-6776-30.2.191","url":null,"abstract":"<p><strong>Objectives: </strong>The primary aim of this project was to improve the rate of prospective pharmacy verification of antibiotics in the emergency department (ED). We also aimed to streamline the process for intravenous (IV) antibiotic preparation and delivery without causing significant delays in antibiotic administration.</p><p><strong>Methods: </strong>This retrospective evaluation compared pharmacist order verification rates for IV and oral antibiotics pre and post intervention between September 2021 and April 2022. Primary intervention involved modifications to the pharmacist verification queue and workflow prioritization. Process measures included time from order placement to pharmacy verification, pharmacy delivery, and administration. Statistical analysis of median times before and after the process change was conducted by using the Mann-Whitney <i>U</i> test. Control charts were used to illustrate the effect of the intervention over the defined period.</p><p><strong>Results: </strong>During the evaluation period, a total of 2545 IV and oral antibiotic doses were ordered in the ED. The process change resulted in an increase in the number of ED IV and oral antibiotic orders verified before administration from 63% (875/1388) to 93% (1076/1157). There were substantial reductions in the pharmacy's median time to IV antibiotic order verification from 21 minutes to 7 minutes (IQR, 4-13; p < 0.05), and median time to IV antibiotic order delivery from 43 minutes to 27 minutes (IQR, 18-38; p < 0.05). Overall time to the first administrated IV antibiotic remained largely unaffected by the process change (50 vs 51 minutes; p = 0.16).</p><p><strong>Conclusion: </strong>Implementation of mandatory pharmacy verification and preparation of IV doses in a high acuity environment like the ED is feasible without compromising antibiotic administration times.</p>","PeriodicalId":37484,"journal":{"name":"Journal of Pediatric Pharmacology and Therapeutics","volume":"30 2","pages":"191-197"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12288566/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144733711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of a Tiered Potassium Replacement Protocol in Post-Operative Patients Admitted to a Pediatric Cardiac Intensive Care Unit. 分级钾替代方案在儿科心脏重症监护病房住院的术后患者中的评价。
Journal of Pediatric Pharmacology and Therapeutics Pub Date : 2025-04-01 Epub Date: 2025-04-14 DOI: 10.5863/1551-6776-30.2.239
Taylor A VandenBerg, Letha A Huang, Chad A Mackman, Jordan L Phillips
{"title":"Evaluation of a Tiered Potassium Replacement Protocol in Post-Operative Patients Admitted to a Pediatric Cardiac Intensive Care Unit.","authors":"Taylor A VandenBerg, Letha A Huang, Chad A Mackman, Jordan L Phillips","doi":"10.5863/1551-6776-30.2.239","DOIUrl":"10.5863/1551-6776-30.2.239","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the efficacy and safety of our institution's tiered intravenous potassium replacement protocol in pediatric patients admitted post-operatively to the pediatric cardiac intensive care unit. To our knowledge, this is the only study evaluating the specific parameters of a potassium replacement protocol similar to ours.</p><p><strong>Methods: </strong>This retrospective, single-center, observational study evaluated children up to 18 years of age admitted post-operatively to the pediatric cardiac intensive care unit between September 1, 2022 and January 31, 2023 who received 1 or more doses of intravenous potassium per our institutional replacement protocol for a hypokalemic episode (serum potassium concentration less than or equal to 3.7 mEq/L). All patients, hypokalemia episodes, replacement doses, and subsequent serum potassium concentrations were evaluated until post-operative day 5.</p><p><strong>Results: </strong>There were 23 patients included with a total of 95 episodes of hypokalemia. For both tiers of the replacement protocol, a median of 1 dose was required to resolve hypokalemia. Two incidences of hyperkalemia (serum potassium greater than or equal to 5.5 mEq/L), 2.1% of total, were proven or suspected to be true, both classified as moderate hyperkalemia. All episodes of hyperkalemia were not associated with ECG abnormalities and did not require treatment.</p><p><strong>Conclusions: </strong>Despite utilizing higher serum potassium concentration thresholds for replacement as well as higher maximum dosing than published literature, our protocol was effective at resolving hypokalemia, as defined by our protocol, without leading to significant hyperkalemia.</p>","PeriodicalId":37484,"journal":{"name":"Journal of Pediatric Pharmacology and Therapeutics","volume":"30 2","pages":"239-244"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12288555/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144733686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aspergillus-Infected Duodenal Perforations Following a Single Dose of Tocilizumab for Pediatric Neuromyelitis Optica. 单剂量Tocilizumab治疗小儿视神经脊髓炎后出现曲霉感染的十二指肠穿孔。
Journal of Pediatric Pharmacology and Therapeutics Pub Date : 2025-04-01 Epub Date: 2025-04-14 DOI: 10.5863/1551-6776-30.2.258
Esther L Albuquerque, Damaris Jacota, Megan Vu, Sarah E Kubes
{"title":"<i>Aspergillus</i>-Infected Duodenal Perforations Following a Single Dose of Tocilizumab for Pediatric Neuromyelitis Optica.","authors":"Esther L Albuquerque, Damaris Jacota, Megan Vu, Sarah E Kubes","doi":"10.5863/1551-6776-30.2.258","DOIUrl":"10.5863/1551-6776-30.2.258","url":null,"abstract":"<p><p>Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune central nervous system disease with inflammatory events recurring in the optic nerves and spinal cord. Neuromyelitis optica (NMO) is rare in children, and pediatric patients typically present with optic neuritis following infections. Lack of response to pulse-dose intravenous corticosteroids or recurrent relapse episodes warrant therapies such as plasma exchange, intravenous immunoglobulin (IVIG), and rituximab. In adult studies, tocilizumab has been used and found to reduce NMO relapse; however, limitations exist in the pediatric population due to the lack of studies and formal treatment guidelines. Gastrointestinal perforation (GIP) is a rare, life-threatening complication identified in clinical trials during tocilizumab therapy. We report a case of a fatal, infected GIP following a single dose of tocilizumab for refractory NMO in a 15-year-old male. This case highlights the need for more outcomes data when using tocilizumab to treat pediatric NMO. Additionally, an assessment of patient-specific risk factors should be outlined to better direct safe therapy and to minimize negative adverse outcomes.</p>","PeriodicalId":37484,"journal":{"name":"Journal of Pediatric Pharmacology and Therapeutics","volume":"30 2","pages":"258-262"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12288552/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144733680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Opportunities for Pharmacogenomics in Pediatrics: Prescribing Trends of Psychiatric Medications With Pharmacogenomic Implications at a Multistate Pediatric Health System. 儿科药物基因组学的机会:在多州儿科卫生系统中药物基因组学影响的精神药物处方趋势。
Journal of Pediatric Pharmacology and Therapeutics Pub Date : 2025-04-01 Epub Date: 2025-04-14 DOI: 10.5863/1551-6776-30.2.245
Megan L Miller, Nathan D Seligson, Benjamin Q Duong, Josephine Elia, Shirin Hasan, Thomas Lacy, Kathryn V Blake, Kelsey J Cook
{"title":"Opportunities for Pharmacogenomics in Pediatrics: Prescribing Trends of Psychiatric Medications With Pharmacogenomic Implications at a Multistate Pediatric Health System.","authors":"Megan L Miller, Nathan D Seligson, Benjamin Q Duong, Josephine Elia, Shirin Hasan, Thomas Lacy, Kathryn V Blake, Kelsey J Cook","doi":"10.5863/1551-6776-30.2.245","DOIUrl":"10.5863/1551-6776-30.2.245","url":null,"abstract":"<p><p>The Clinical Pharmacogenetics Implementation Consortium (CPIC) has published guidelines providing pharmacogenomic (PGx) recommendations for more than 100 drugs; however, limited data exist describing prescribing patterns of these medications in pediatric populations. With increasing evidence describing the benefits of PGx testing to tailor drug therapy in psychiatric conditions, along with a worsening mental health crisis in pediatrics, it is vital to assess the prevalence of medication prescribing and potential impact of implementing PGx testing in this population. Here we describe prescribing patterns of psychiatric drugs classified as CPIC level A/B from January 1, 2010, through December 31, 2020, across Nemours Children's Health, a multistate pediatric health care system. We identified 21,442 unique patients who received at least 1 indicated medication during this period. The most frequently prescribed medications were amitriptyline and sertraline. Overall prescribing was highest in the departments of neurology, primary care, and psychiatry with selective serotonin reuptake inhibitors (SSRIs) being the most frequently prescribed medication class. These findings indicate ample opportunity for PGx implementation targeting these medications. Identification of high-prescribing departments and specific medications prescribed will help focus PGx implementation and education efforts.</p>","PeriodicalId":37484,"journal":{"name":"Journal of Pediatric Pharmacology and Therapeutics","volume":"30 2","pages":"245-249"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12288568/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144733707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信